Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Quantitative Research on a Voluntary Symbol Depicting the Nutrient Content Claim “Healthy” on Packaged Foods, 17300-17307 [2022-06419]
Download as PDF
17300
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
ANNUAL BURDEN ESTIMATES
Instrument
Number of
respondents
(total over request period)
Number of
responses per
respondent
(total over request period)
Average
burden per
response
(in hours)
Total burden
(in hours)
Total burden
(in hours)
Annual burden
(in hours)
Construction Worker Survey ....................
4,200
1
1
0.5
2,100
1,050
Estimated Total Annual Burden
Hours: 1,050.
Authority: Section 105(d)(2) of the
Trafficking Victims Protection Act of
2000 (Pub. L. 106–386) [22 U.S.C. 7103].
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2022–06415 Filed 3–25–22; 8:45 am]
BILLING CODE 4184–47–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0709]
Prescription Drug User Fee Rates for
Fiscal Year 2022; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
notice entitled ‘‘Prescription Drug User
Fee Rates for Fiscal Year 2022’’ that
appeared in the Federal Register of
August 16, 2021. The document
announced the Fiscal Year 2022 fee
rates for the Prescription Drug User Fee
Act. The document published with
errors. The errors did not have an
impact on the previously published user
fee rates but are corrected in this
document for clarity.
FOR FURTHER INFORMATION CONTACT:
Misbah Tareen, Office of Financial
Management, Food and Drug
Administration, 4041 Powder Mill Rd.,
Rm. 61077A, Beltsville, MD 20705–
4304, 301–796–3997.
SUPPLEMENTARY INFORMATION: In the
Federal Register of August 16, 2021 (86
FR 45732), appearing on page 45736 in
FR Doc. 2021–17505, the following
corrections are made:
1. In the second column, in the last
sentence of the third paragraph under
‘‘D. FY 2022 Statutory Fee Revenue
Adjustments for Operating Reserve’’,
‘‘both user fee funds available for
obligation $126,873,636 and funds that
are considered unavailable due to a lack
of appropriations $98,850,995’’ is
corrected to read ‘‘user fee funds
considered unavailable due to a lack of
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
appropriations $78,850,995, additional
fee funds that are available for
obligation but set aside for future year
refunds as a matter of prudent
operations $20,000,000, and carryover
net of unavailable funds and the setaside $126,873,636.’’
2. The fourth footnote is corrected by
removing the text and replacing it with:
‘‘In recent PDUFA Annual Financial
Reports, the category ‘‘unavailable for
use’’ has been used to refer both to (1)
fee funds that are considered
unappropriated and (2) appropriated fee
funds the Agency has maintained to
provide for any refunds. FDA intends to
discontinue use of the category
‘‘unavailable for use’’ in forthcoming
reports to better reflect the difference
between these line items and improve
the clarity of its reporting. Although
certain amounts have been maintained
for future refunds as a matter of prudent
operations, these amounts are
considered appropriated and are
available for obligation.’’
3. In the second column, in the fifth
paragraph under ‘‘D. FY 2022, Statutory
Fee Revenue Adjustments for Operating
Reserve’’, sentences 4 through 7 are
corrected by removing the text and
replacing it with ‘‘FDA has decided to
make an available operating reserve
adjustment that is intended to increase
the amount of available funds to
approximately 8 weeks by the end of FY
2022, representing the low end of the 8to 10-week range while mitigating the
impact on fee amounts. FDA estimates
the cost of operations per week is
$22,144,672. Before the operating
adjustment, the estimated end of year
FY 2022 available operating reserve is
$145,677,240, which equates to about
61⁄2 weeks of available operating
reserves. Adding the FY 2022 operating
reserve adjustment of $39,402,923 to
this amount is expected to provide
approximately 8 weeks of available
operating reserve, or $185,080,162
(including $20,000,000 in available fee
funds maintained for any future
refunds), and a total carryover of
operating reserves (including
unavailable funds) of $263,931,157.’’
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Dated: March 21, 2022.
Andi Lipstein Fristedt,
Deputy Commissioner for Policy, Legislation,
and International Affairs, U.S. Food and Drug
Administration.
[FR Doc. 2022–06427 Filed 3–25–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0336]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Quantitative
Research on a Voluntary Symbol
Depicting the Nutrient Content Claim
‘‘Healthy’’ on Packaged Foods
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(PRA).
DATES: Submit written comments
(including recommendations) on the
collection of information by April 27,
2022.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be submitted to https://
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function. The title
of this information collection is
‘‘Quantitative Research on a Voluntary
Symbol Depicting the Nutrient Content
Claim ‘Healthy’ on Packaged Foods.’’
Also include the FDA docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Operations, Food
and Drug Administration, Three White
SUMMARY:
E:\FR\FM\28MRN1.SGM
28MRN1
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–7726, PRAStaff@
fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Quantitative Research on a Voluntary
Symbol Depicting the Nutrient Content
Claim ‘‘Healthy’’ on Packaged Foods
OMB Control Number 0910–NEW
jspears on DSK121TN23PROD with NOTICES1
I. Background
Section 403(r)(1)(A) of the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 343(r)(1)(A)) permits the
use of label and labeling claims that
characterize the level of a nutrient in a
food when the claims are made in
accordance with FDA’s regulations.
Such claims are referred to as ‘‘nutrient
content claims.’’ We have issued
regulations under section 403(r)(1)(A) of
the FD&C Act describing ‘‘implied
nutrient content claims’’ as those that,
among other things, suggest that a food,
because of its nutrient content, may
help consumers maintain healthy
dietary practices (21 CFR 101.65(d)(1)(i).
The rule finalizing these claims also
describes implied claims, in part, as
those that imply that a food, because of
its nutrient content, may be useful in
achieving a total diet that conforms to
current dietary recommendations
(‘‘Food Labeling: Nutrient Content
Claims, General Principles, Petitions,
Definition of Terms,’’ 58 FR 2302 at
2374, January 6, 1993)). We have
determined that a claim that a food,
because of its nutrient content, may be
useful in maintaining healthy dietary
practices is clearly a claim that
characterizes the level of nutrients in
that food. The claim is essentially
saying that the level of nutrients in the
food is such that the food will
contribute to good health (58 FR 2302 at
2375). In 1994, we issued a definition of
‘‘healthy’’ as an implied nutrient
content claim (59 FR 24232, May 10,
1994); the regulation is codified at 21
CFR 101.65(d)(2).
FDA seeks to improve dietary patterns
in the United States to help reduce the
burden of diet-related chronic diseases
and advance health equity. We are
committed to accomplishing this by, in
part, empowering consumers with
information to make more informed
dietary choices. To help advance these
goals, we are exploring the development
of a graphic symbol to help companies
communicate and consumers identify
packaged food products that meet FDA’s
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
definition of ‘‘healthy.’’ The symbol
would be a graphic representation of the
nutrient content claim ‘‘healthy’’ and,
like the implied nutrient content claim
‘‘healthy’’ itself, would be voluntary for
packaged food companies. Companies
could voluntarily use the symbol on
food products that meet FDA’s
definition of ‘‘healthy.’’
In 2019 and 2020, FDA conducted a
review of the literature on front-ofpackage (FOP) nutrition-related symbols
and conducted a series of focus groups
to test symbol concepts and draft FOP
symbols (see Docket No. FDA–2021–N–
0336 for the literature review and a table
of draft FOP symbols).
As part of our efforts to promote
public health, we intend to conduct two
consecutive quantitative research
studies—a survey (Study 1) and an
experimental study (Study 2) to explore
consumer responses to the draft FOP
symbols that companies could
voluntarily use on a food product as a
graphic representation of the nutrient
content claim ‘‘healthy.’’ If research
results suggest the need, the symbols
will be fine-tuned following the survey
and again following the experimental
study. Study 1 will use non-probability
survey methods, using a web-based
panel to draw a sample of 2,000 U.S.
adults ages 18 and older who selfidentify as primary food shoppers. The
sample will be balanced to the
demographics of the U.S. population.
The survey instrument will focus on
clarity, relevance, and appeal of a set of
symbols.
Study 2 will be a controlled,
randomized experiment that will use a
15-minute web-based questionnaire to
collect information from 5,000 U.S.
adult members of an online consumer
panel. Conditions for Study 2 will be:
(1) A set of draft FOP symbols,
including ‘‘no-symbol’’ controls; (2)
three types of mock food products (i.e.,
a breakfast cereal, a frozen meal, and a
canned soup); (3) a ‘‘no-information’’
condition where no explanation of the
symbol is provided; and; (4) a Uniform
Resource Locator (URL) condition, in
which a URL is tested alongside the
symbol. Each participant in Study 2 will
be randomly assigned to a condition,
which will include viewing a label
image and responding to various
measures of the symbol’s effectiveness.
Measures of response in the experiment
will include product perceptions (e.g.,
healthfulness and contribution to a
healthy diet), label perceptions (e.g.,
believability, trustworthiness, message
effects), and purchase/choice questions.
The instrument will also collect
information from participants about
their history of purchasing or
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
17301
consuming similar products; nutrition
knowledge; dietary interests; motivation
regarding label use; health status; and
demographic characteristics.
The studies are part of our continuing
effort to enable consumers to make
informed dietary choices and construct
healthful diets. We intend to use the
results to inform our continued
exploration of a symbol manufacturers
could voluntarily use to represent the
nutrient content claim ‘‘healthy’’ on the
food label. We will not use the results
to develop population estimates.
Description of Respondents:
Respondents to this collection of
information include members of the
general public.
In the Federal Register of May 7, 2021
(86 FR 24629), FDA published a 60-day
notice requesting public comment on
the proposed collection of information
(‘‘60-day notice’’). We received 43
comments, 27 of which were PRArelated. The remaining comments were
non-responsive to the four PRA topics,
and so we will not address them in this
document.
A. Comments Regarding the Necessity
and Practical Utility of the Information
Being Collected and FDA Response
Several comments addressed the
necessity and practical utility of
collecting information on a voluntary
symbol depicting the nutrient content
claim ‘‘healthy’’ on packaged foods.
(Comment 1) Some comments
supported FDA’s proposed collection of
information through the three proposed
quantitative consumer research studies.
Some comments expressly supported
FDA’s end research goal of enabling
consumers to make informed dietary
choices and construct healthful diets.
Some supported FDA’s intention to
understand consumer responses to draft
FOP symbols and gather data and other
information to inform our thinking on a
‘‘healthy’’ symbol. Many comments
indicated the importance of conducting
this research before taking regulatory
action on any symbol. Some comments
supported conducting the research in
conjunction with development of a
proposed rule that would update the
definition of ‘‘healthy’’ on food
packages.
Other comments opposed FDA
research on a ‘‘healthy’’ symbol. Some
of these comments suggested the
research is unnecessary, claiming that a
single food is not ‘‘healthy’’ or
‘‘unhealthy,’’ that overall diet matters
more than individual foods, or that
symbols are industry marketing. A few
comments suggested a ‘‘healthy’’ symbol
could be particularly misleading to, or
misinterpreted by, people who are
E:\FR\FM\28MRN1.SGM
28MRN1
jspears on DSK121TN23PROD with NOTICES1
17302
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
experiencing eating disorders. Some
comments also questioned whether a
‘‘healthy’’ symbol would: (1) Have a
positive and meaningful impact on
improving health or (2) lead consumers
to overconsume foods bearing the
symbol.
(Response 1) We intend to conduct
this research now, in conjunction with
further work on updating our definition
of the claim ‘‘healthy’’ and before taking
regulatory action on any symbol. Our
intended research will help us better
understand how consumers might
respond to and use a graphic symbol to
identify packaged food products that
meet our definition of ‘‘healthy.’’ This
research will help address many points
raised in the comments, such as how
consumers might react to and
understand a ‘‘healthy’’ symbol and
misinterpretations they may have.
While we agree that there are some
symbols that may be used exclusively
for industry marketing, companies
could use any FDA ‘‘healthy’’ symbol
we develop and finalize only when the
product displaying the symbol meets
FDA’s regulatory definition of
‘‘healthy.’’ This could help consumers
make more informed dietary choices
and construct healthful diets. The
comments claiming that a single food is
not ‘‘healthy’’ or ‘‘unhealthy’’ and that
overall diet matters more than
individual foods are commenting on the
‘‘healthy’’ claim itself, which we do not
intend to test in this research. Rather,
we intend to test consumer reactions to
symbols that could be a graphic
representation of the claim.
Nonetheless, we note that a ‘‘healthy’’
symbol, such as the ones FDA is
exploring in our research, could help
consumers choose food products, as
part of their overall diet, that meet
FDA’s regulatory definition of
‘‘healthy.’’ The research is not designed
to study long-term health effects or
consumer consumption patterns. We
reiterate that this research is about
graphical representations of the nutrient
content claim ‘‘healthy’’—in other
words, we intend to study only the
symbol, not the claim itself. Depending
on the results of this data collection, we
may decide to test additional symbols or
revise our current symbols.
(Comment 2) Many comments
expressed a preference for conducting
the research after we revise our
regulatory definition of ‘‘healthy,’’ as
they wondered whether the definition of
the claim could influence both the
design and consumer understanding of
the symbol. Some expressed concern
that testing a symbol without clearly
communicating what the symbol means
could lead to ambiguous results. One
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
comment expressed concern that, by
conducting testing only on the symbols
in the notice, we would not consider
testing any other symbols in the future.
A few comments contended that FDA’s
testing would be invalid if the mock
products used in testing do not meet
FDA’s updated ‘‘healthy’’ definition.
(Response 2) FDA has an existing
definition for the claim ‘‘healthy,’’ and
in the Federal Register of September 28,
2016, we announced our intent to
exercise enforcement discretion around
some criteria for the claim (see ‘‘Use of
the Term ‘Healthy’ in the Labeling of
Human Food Products: Guidance for
Industry,’’ 81 FR 66527). However, as
part of this data collection, we have
included experimental conditions in
which participants will read general
information outlining the use of the
claim ‘‘healthy’’ only for purposes of
this study. This will help us better
understand how consumers might
respond to the symbols we are
proposing to test if participants
understand a ‘‘healthy’’ definition, even
if not necessarily an updated definition.
While the symbol is intended to
represent the nutrient content claim
‘‘healthy,’’ our research on the symbol is
not dependent on specific criteria for
‘‘healthy.’’ We are researching general
consumer perceptions and impressions
of the symbols themselves, not the
definition that may underly those
symbols, and as such, we do not need
to wait until we have a final, updated
regulatory definition of ‘‘healthy’’ before
conducting this research. Moreover, the
symbols being tested would not need to
be modified with a changing definition
of ‘‘healthy;’’ the symbol would remain
a simple graphic representation of the
‘‘healthy’’ claim.
Regarding the claim that our testing
would be invalid if the mock products
used in testing do not meet FDA’s
updated ‘‘healthy’’ definition, our mock
products represent broad and basic food
categories. They include foods such as
vegetables and whole grains with
limited nutrients of concern (e.g.,
sodium or saturated fat) that would
meet our current definition of ‘‘healthy’’
and would help consumers build a diet
consistent with the Dietary Guidelines
for Americans, 2020–2025.
B. Comments Regarding the Accuracy of
Our Burden Estimates, Including the
Validity of the Methodology and
Assumptions Used, and FDA Response
Many comments discussed the
accuracy of FDA’s estimate of the
burden for this information collection,
including the validity of FDA’s
methodology and the assumptions used.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
(Comment 3) Several comments
alleged that we provided limited details
about our proposed research studies and
encouraged us to publish additional
information on the proposed scope and
methodology of our consumer research
to allow for more comprehensive input
from experts in the field of consumer
research. One comment suggested we
‘‘pre-register’’ details of the proposed
studies on AsPredicted.org or
ClinicalTrials.gov so that stakeholders
could better understand the primary
outcome of the research, hypotheses,
analytic plan, and power analysis used.
(Response 3) We described the
research in the 60-day notice, providing
information on research design,
measures, sampling, and sample size.
Many comments substantively
addressed these issues, and so we
believe there was enough information
about the studies in the 60-day notice
for the public—including consumer
researchers—to comment on the
research.
We specified in the 60-day notice that
we intend to use the results to inform
our continued exploration of a symbol
manufacturers could voluntarily use to
represent the nutrient content claim
‘‘healthy’’ on the food label (86 FR
24629 at 24631). The comment did not
provide sufficient information regarding
additional details that it believed
necessary for stakeholders to better
understand this primary outcome,
hypotheses, analytic plan, and power
analysis used, and it did not explain
what additional details might be
available via pre-registration that would
not be available in our Federal Register
notices. Therefore, we are unable to
provide those details here, and we also
decline to pre-register our studies.
(Comment 4) One comment
questioned the ordering of the
quantitative research, asking why the
experimental studies come before the
surveys. Other comments suggested we
use the two surveys to test draft symbols
first to narrow down options and test
the ‘‘final’’ symbols in the experiment,
or to conduct preliminary research to
narrow the options for the experiment.
(Response 4) We conducted several
phases of qualitative research to solicit
input from consumers, allowing us to
evaluate symbol prototypes and design
elements to learn what resonated with
consumers. Through that process we
narrowed our draft symbol options.
After considering public comments, we
have reconsidered the order of the
research, and plan to conduct one
survey with a larger sample size (instead
of two surveys with smaller sample
sizes each) before the experimental
study. In other words, we will reorder
E:\FR\FM\28MRN1.SGM
28MRN1
jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
the studies and combine the two
surveys into one, which will allow us to
test all symbols in a single survey.
While our proposed information
collection is intended to help us better
understand how consumers might
respond to and use a graphic symbol
that indicates packaged food products
meet FDA’s definition of ‘‘healthy,’’ and
all the draft symbols we proposed to test
would allow us to do that, we expect
conducting a single survey first will
help us further revise and narrow down
the set of symbols.
(Comment 5) One comment suggested
we use a more naturalistic study
environment, such as an online store
setting, instead of using images.
(Response 5) Online store settings and
other naturalistic study environments
have been successfully employed in
some studies on food labeling effects.
One advantage of employing such
naturalistic study environments is that
they more closely reflect participants’
actual shopping experience. However,
there are substantial additional costs
associated with using such research
settings, and results in these settings
generally do not differ appreciably from
results garnered through the simple
random-assignment-to-condition design
that we proposed. Therefore, we decline
to change our study environment.
(Comment 6) One comment suggested
that FDA separate different aspects of
the symbols to isolate consumer
perceptions of the word ‘‘healthy,’’ the
graphic itself, and the graphic
accompanied by the word ‘‘FDA.’’ One
comment suggested that FDA should
test each symbol with and without
‘‘FDA.’’
(Response 6) Separating each aspect
of the symbols for our testing would
increase the number of conditions
exponentially, making the design
impractical. We instead elected to use a
full factorial design with simple random
assignment to condition, to give us
results on the performance of the
various symbol designs. Using random
assignment to condition, we may be able
to eliminate some symbols without
needing to test particular attributes in
any one symbol. We may consider
alternate study designs when we have a
narrower set of symbols.
One finding of our literature review
was that institutional endorsement may
be related to greater confidence in the
symbol. Our focus group research
affirmed that participants regarded
symbols with ‘‘FDA’’ as more
trustworthy than symbols without
‘‘FDA.’’ Therefore, for the intended
research, we are testing draft symbols
with ‘‘FDA.’’ We may consider
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
additional research on this point
depending on the results.
(Comment 7) One comment
recommended using images of real food
products in the experimental studies
instead of using mock product images.
(Response 7) FDA does not agree with
the recommendation to use images of
real products in the experimental
studies. Mock images remove the
potential for brand biases, a source of
response error that has been
demonstrated to affect the way
individuals answer survey questions.
Mock food product labels
psychologically remove the salience of
branded product informational cues
present in the retrieval stage of the
response process (Refs. 1 and 2).
Additionally, the mock product labels
we designed are visually similar to
labels consumers could expect to see in
stores for each given product category.
We confirmed this assertion in our
qualitative testing by noting that
participants perceived the mock product
labels as ones with which they were
unfamiliar, but which were plausible for
the food product depicted.
(Comment 8) One comment suggested
that we should assess ‘‘multi-tier
symbols’’ in addition to the symbols we
intend to test. The comment suggested
that multi-tier symbols are those that
use, for example, an increasing number
of stars to indicate to the consumer that
a choice is ‘‘good,’’ ‘‘better,’’ or ‘‘best.’’
The comment argued that a multi-tiered
approach could encourage consumers to
make incremental improvements in
their diets, enable manufacturers to
reformulate products to meet the initial
tier of the system, and increase the
number of foods with at least some
healthful benefits that could carry a
symbol.
Another comment suggested that FDA
consider a symbol that warns consumers
about high levels of unhealthy nutrients.
Another comment asserted that we
should also test what it suggested were
more neutral FOP labels, such as traffic
lights, nutrition scoring symbols, and
warning symbols, to better assist
consumers in making healthy choices
and motivate manufacturers to make
healthier foods.
(Response 8) For the purpose of this
study, we are testing only symbols that
would be a graphic representation of the
nutrient content claim ‘‘healthy’’—a
food that could bear that claim could
also bear the symbol. FDA’s systematic
literature review suggested that a
summary indicator—the type we are
proposing to test—would have the
greatest utility to depict the ‘‘healthy’’
claim to a broad array of consumers,
especially those with lower education or
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
17303
lower health literacy. As such, we
disagree that we should test other kinds
of symbols to depict the nutrient
content claim ‘‘healthy.’’ We are testing
different draft symbol designs based on
our literature review and the feedback
we collected through our focus group
research. Our current study plans are
limited to testing summary symbols
depicting the nutrient content claim
‘‘healthy’’ to get reactions to design
elements and to reduce the current
number of symbols under consideration.
Because there are no ‘‘healthy’’ tiers in
the nutrient content claim, we decline
to test a tiered symbol.
(Comment 9) One comment
encouraged us to consider testing the
‘‘healthy’’ symbol alongside other
current voluntary FOP labels—rather
than as the only symbol on a package—
to determine the effect of other FOP
labels on the efficacy of the ‘‘healthy’’
symbol.
(Response 9) Our studies are designed
to test general consumer responses to
the symbols presented. Testing
additional variables, such as the effect
of other packaging elements on the
symbols, is outside the scope of this
research. We may decide to test
‘‘healthy’’ symbols alongside other FOP
symbols in later research depending on
the results from this data collection.
(Comment 10) One comment
recommended randomizing participants
to see subgroups of symbols, claiming it
would be an efficient use of resources.
(Response 10) FDA agrees with the
recommendation that participants be
randomly assigned; however, we
disagree with the recommendation to
have participants view subgroups of
symbols. We plan to randomly assign
participants to see a single symbol
condition, including product type,
information on the definition of healthy,
URL/no-URL, and set of symbols.
Viewing a single symbol condition
precludes the effects of biases that may
result from having viewed and
responded to questions about one
symbol affecting responses about
another symbol (Ref. 1). Therefore, even
if we might use fewer resources by
assigning participants to see subgroups
of symbols, the practice would
introduce biases and confounds that
could make interpreting the results very
difficult.
(Comment 11) One comment
recommended incorporating time limits
for a choice task to better mimic real-life
scenarios where consumers have only
limited time to shop.
(Response 11) The current
experimental study design is random
assignment to condition with no
‘‘choice task.’’ While time-constraint
E:\FR\FM\28MRN1.SGM
28MRN1
jspears on DSK121TN23PROD with NOTICES1
17304
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
studies can be useful to test certain
variables, our research goal is for the
participants to provide thoughtful
responses, unaffected by the stress that
a time limit could impose.
(Comment 12) A few comments
recommended that the studies be
adequately powered to enable FDA to
do appropriate statistical analysis.
(Response 12) Our studies are
designed to have the appropriate
statistical power to conduct all
necessary statistical analysis. We will
test hypotheses related to between-label
differences. We will impose no a priori
direction of differences, if any (i.e., we
assume all tests are two-tailed). The
target sample size (5,000 for the
experimental study and 2,000 for the
survey) will yield enough observations
to provide adequate power to identify 4way interactions of a medium size (Ref.
3).
(Comment 13) One comment
recommended that we test the draft
‘‘healthy’’ symbols in the context of
restaurants.
(Response 13) Our research plans
include testing symbols solely on
packaged foods. Testing ‘‘healthy’’ on a
packaged food label versus in a
restaurant minimizes the many
confounding factors inherent in
studying claims in a restaurant
environment, such as the enormous
variance in size and content of materials
used to sell restaurant food. Keeping the
studies limited to packaged food labels
allows FDA to better isolate various
effects of the symbols to strictly test
consumer perceptions about the
symbols. Additionally, as we noted in
response to another comment, we have
no reason to believe that adding
additional test product categories would
change the study outcomes given our
goal of testing consumer responses to
the symbols.
(Comment 14) Some comments
recommended that FDA include more
than three mock product types in the
experimental studies because of the
potential that consumer perceptions of a
‘‘healthy’’ symbol might be different on
different products. One comment
suggested including a variety of food
categories in the studies, while a few
other comments recommended
including specific product categories,
including beverages and fresh produce,
so FDA could assess consumer reactions
to, or preferences for placement of, a
symbol on those products.
(Response 14) FDA disagrees with the
recommendation to add more product
types to the studies. We are proposing
to test ‘‘healthy’’ symbols on a set of
mock products that belong to large food
categories, with many product types
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
within each category. The broad product
categories for those mock products are
likely to contain multiple products that
currently meet FDA’s regulatory
definition of ‘‘healthy.’’
For our research, we chose three
packaged foods that are commonly
consumed and that are clearly distinct
food types. The selected products will
give us sufficient information on general
consumer responses to the symbols to
continue development of a proposed
‘‘healthy’’ symbol. We also note that
adding any products would increase the
scope and cost of the studies while
providing limited new information and
that the comments provided no
evidence that additional test products
from other food categories would impact
our study outcome.
We decline to include a beverage as
one of the mock products. While
beverages that meet FDA’s definition of
‘‘healthy’’ could bear any ‘‘healthy’’
symbol we finalize, the same is true of
any packaged food, and as we explained
above, we have no reason to believe that
adding additional test product
categories would change the study
outcomes. We decline to add fresh
produce to the studies for the same
reasons.
(Comment 15) A few comments
recommend comparing foods with a
‘‘healthy’’ symbol and foods that may
have healthful attributes but do not
meet the regulatory definition of
‘‘healthy,’’ to evaluate whether use of
the symbol might result in discouraging
purchase of foods that have important
nutrients but that do not meet the
definition of ‘‘healthy.’’ Another
comment suggested testing a variety of
products (‘‘healthier’’ and ‘‘less
healthy’’) for each food product category
included in the studies.
(Response 15) The studies are not
designed to test purchasing behavior,
and so we decline to add mock products
for that purpose. Rather, this research is
designed to test general consumer
responses to the symbols themselves.
Additionally, a product could only bear
the symbol if it qualified to bear the
‘‘healthy’’ claim itself—the symbol is a
graphic representation of the claim—
and we are not testing the claim
definition or its effects here.
One of the study assumptions is that,
like the nutrient content claim
‘‘healthy,’’ any food bearing a ‘‘healthy’’
symbol on its label must meet the
regulatory definition of ‘‘healthy.’’
Therefore, to test consumer responses to
the symbols, we do not need to test the
ancillary effects of a ‘‘healthy’’ symbol
on foods that do not bear the claim.
Moreover, FDA intends to test ‘‘healthy’’
symbols on a set of mock products
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
whose product categories are likely to
contain multiple products that currently
meet FDA’s regulatory definition of
‘‘healthy’’—we are making no claims
about the relative healthfulness of any
product. Using these mock products in
our research will provide us with
sufficient information to understand
how consumers might respond to a
‘‘healthy’’ symbol on food packaging,
and that information is our goal with
these studies. Testing the selected
products will give us sufficient
information to continue development of
a proposed ‘‘healthy’’ symbol.
The comment did not provide an
explanation for its recommendation to
test ‘‘healthier’’ and ‘‘less healthy’’
products for each food product category.
We are not testing ‘‘healthier’’ and ‘‘less
healthy’’ versions of a given product in
this research effort, as the goal of the
research is to gauge participants’
reactions to a symbol. Additionally, we
are working on updating our definition
of ‘‘healthy’’ and will describe our
proposed updated definition in any
related rulemaking. It would be
inappropriate to assign relative
‘‘healthfulness’’ to comparator products.
Products bearing the ‘‘healthy’’ symbol,
which would be a graphic version of the
nutrient content claim ‘‘healthy,’’ would
have to meet the criteria for using the
claim.
(Comment 16) One comment noted a
symbol with the term ‘‘FDA’’ may cause
confusion if that symbol is used on any
products regulated by the U.S.
Department of Agriculture (USDA) and
urged us to consider the potential for
such confusion in our research. Another
suggested that we engage with the Food
Safety and Inspection Service during
our proposed consumer research on the
‘‘healthy’’ symbol to develop a symbol
that could apply to all products that
meet the ‘‘healthy’’ claim criteria.
(Response 16) We cannot comment on
whether or how USDA might allow an
FDA ‘‘healthy’’ symbol on the products
it regulates that meet FDA’s definition
of ‘‘healthy.’’ However, we intend to
coordinate with our federal partners,
including USDA, as appropriate, as we
continue our work on a ‘‘healthy’’
symbol.
(Comment 17) A few comments
asserted it was important to consider the
symbols’ placement on packaging and
noted that food packaging size, type,
and appearance vary, suggesting that
FDA should study how consumers may
respond to a ‘‘healthy’’ symbol on a
wider variety of packaging formats than
are currently proposed for the studies.
One comment suggested testing the
symbol on different locations on the
package and with varying prominence.
E:\FR\FM\28MRN1.SGM
28MRN1
jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
Another encouraged flexibility in
specified requirements (e.g., placement,
type size, color format, scannable
images) surrounding the FOP symbol.
(Response 17) We anticipate that any
‘‘healthy’’ symbol we propose would be
standardized in certain ways. However,
the purpose of this research is to gauge
consumer responses to the symbols we
are testing, not to decide on a single
symbol, its potential placement on
packaging, or what aspects we would
require, should a company choose to
use the symbol.
(Comment 18) A few comments
suggested we include questions or
conduct additional research to assess
the potential for consumer
misunderstanding of the symbols. Some
comments suggested that we investigate
whether consumer perceptions of some
symbols might imply messages other
than ‘‘healthy’’ (such as ‘‘organic,’’
‘‘natural,’’ ‘‘plant-based,’’ and
‘‘minimally processed’’) or whether the
symbols we are testing may appear
similar to other existing or abandoned
symbols (such as the USDA Organic
Seal, Smart Choices, or any of USDA’s
bioengineered food symbols). One
comment claimed that a lack of
legibility of the text in the symbol could
cause consumer confusion. Another
comment recommended that FDA avoid
leaf or nature imagery in the symbol
because it could imply that the product
is plant-based, ‘‘natural,’’ or
unprocessed. One comment encouraged
us to examine how appealing the
symbols are to consumers, and another
comment described the proposed
symbols as too simplistic.
(Response 18) We have selected study
designs and draft symbols that we
expect, when used together, will reveal
how consumers will react when they see
such symbols on a food label. We
included questions in our studies on
what the symbols lead participants to
believe about the products bearing
them. We also expect to hear from
participants whether the symbols we are
testing are perceived as too complex, too
simplistic, or invoke concepts other
than ‘‘healthy.’’
We agree that any symbol we propose
should be legible and minimize imagery
that our research indicates could widely
lead consumers to think the symbol
means something unintended. As such,
we will add an open-ended question to
the experimental study asking what the
symbol brings to mind to help
determine if any symbols should be
removed from consideration or revised
on this basis. Moreover, we agree that
the FDA symbol design for ‘‘healthy’’
should not be easily confused with
other existing symbols and should be
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
viewed as professional and credible by
consumers. We expect to get some data
on these points through this round of
testing and may undertake further
research before we make any formal
regulatory decision on a symbol.
(Comment 19) One comment
suggested that FDA test other terms
besides ‘‘healthy,’’ such as ‘‘nourishing’’
or ‘‘nutrient-dense.’’
(Response 19) We are not testing the
nutrient content claim ‘‘healthy;’’ rather,
we are testing consumer responses to
graphic representations of the claim. We
similarly do not intend to test other
terms.
(Comment 20) Several comments
supported conducting research on the
use of an accompanying URL with the
‘‘healthy’’ symbol; however, others
stated the purpose for including a URL
was unclear, and one comment
expressed concern that a URL would not
work as well in a brick-and-mortar retail
setting. Another comment stated that
future labeling could include the use of
other technologies, such as a quick
response (QR) code or digital
watermark, to provide consumers access
to all the labeling information included
on the package and suggested that we
incorporate digital disclosure flexibility
into our labeling regulations because
technology continues to evolve. Other
comments suggested that consumers
may not have internet access in stores
or may not know how to use QR codes,
while another comment suggested that
researchers could develop unique QR
codes for each condition and track
participant use.
(Response 20) Our research efforts on
the ‘‘healthy’’ symbol are intended to
collect sufficient data for the
development and finalization of a
‘‘healthy’’ symbol. We are studying
several dimensions of a proposed
symbol, including the inclusion of a
URL as part of the symbol. This research
will help us better understand study
participants’ reactions to and
understanding of those different
elements.
Our preliminary research indicated
that participants are interested in
learning more about the symbols, and a
URL can serve as a representation to
participants that more information is
available. The current study design
proposes to test a URL alongside some
of the symbols to gauge the ability of the
URL to indicate that information about
the symbol is available and to assess the
degree to which a URL improves
confidence and trust in the symbol. We
are not studying participants’ actual
ability to access the URL in stores or
elsewhere. We are also not considering
inclusion of other technologies, such as
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
17305
a QR code or digital watermark, in this
information collection because a URL
will help us gauge whether participants
want a way to access additional
information about the symbol. Further,
a QR code or digital watermark would
not indicate government involvement in
the way a URL ending ‘‘.gov’’ may, and
we are interested in how participants
will respond to a ‘‘.gov’’ URL.
While we agree that technology
changes over time, we are only studying
consumer responses to the symbols in
this research. It would be premature to
comment on any requirements
surrounding any symbol we might
propose. However, we could consider
other digital elements, such as QR codes
or digital watermarks, in future research
depending on our future research goals.
(Comment 21) Some comments raised
concerns that the use of FDA’s name as
part of the ‘‘healthy’’ symbol. The
comments said that the use of FDA’s
name could create the appearance of an
FDA endorsement of a given food.
(Response 21) We are testing draft
symbols with ‘‘FDA.’’ We note that we
are studying several dimensions of a
proposed symbol to help us better
understand study participants’ reactions
to and understanding of those different
elements, including any impression of
an FDA endorsement.
(Comment 22) A few comments
expressed uncertainty as to whether
FDA research participants would come
from a nationally representative sample
and recommended paying particular
attention to or using quota samples
similar to the demographic breakdown
of the U.S. population regarding sex,
age, race/ethnicity, income, and
education. Some comments also stated
that FDA should consider oversampling
from certain groups at highest risk for
dietary-related disparities, asserting that
it is important to ensure that any
proposed healthy symbol works well
among all populations. One comment
noted this is especially important for
lower-education groups who, the
comment asserted, may be less likely to
use or understand the package’s
nutrition label. Some comments also
requested that FDA screen participants
to ensure a sample large enough to
collect responses from food-allergic
individuals, caregivers to food-allergic
individuals, and parents.
(Response 22) We designed our
studies to test consumer responses to
draft symbols in a randomized
controlled setting, with participants
drawn from a general population. Our
research collection is not intended to
produce population estimates. However,
we intend to select the samples in each
study to be reflective of the general U.S.
E:\FR\FM\28MRN1.SGM
28MRN1
17306
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
population (e.g., sex, race/ethnicity). We
believe our approach is reasonable
because any ‘‘healthy’’ symbol we
finalize will be available to the general
U.S. population.
(Comment 23) One comment
suggested that we test a Spanish
language version of the symbol and
consider whether including ‘‘FDA’’ as
part of the symbol would resonate with
consumers of products sold in other
countries.
(Response 23) Our regulations, at 21
CFR 101.15(c), generally require that the
labeling of all food offered for sale in the
United States be in English, and outline
requirements for manufacturers that also
choose to label their products in
additional languages. Because we
generally require only English labeling,
and manufacturers may choose whether
to use or include foreign-language
labeling, we are testing only an Englishlanguage version of the symbol in this
set of studies.
As for products sold in other
countries, the nutrient content claim
‘‘healthy,’’ and any related symbol we
finalize, are specifically for products
marketed and sold in the United States.
We decline to comment on marketing
and sales in, or the food labeling
requirements of, other countries.
(Comment 24) One comment argued
that we should not generalize the results
from this study to all FOP label systems.
(Response 24) We agree that findings
from this research should not be
generalized to all FOP label systems.
jspears on DSK121TN23PROD with NOTICES1
C. Comments Regarding Ways To
Enhance the Quality, Utility, and Clarity
of the Information To Be Collected, and
FDA Response
Several comments suggested ways to
enhance the quality, utility, and clarity
of the information about ‘‘healthy’’
symbols to be collected.
(Comment 25) Some comments stated
FDA should conduct thorough research
regarding the development and
finalization of a symbol for ‘‘healthy,’’
and should collect comprehensive data
so that FDA’s final decision promotes
health.
(Response 25) FDA agrees with the
comments. Our research goal is to
explore consumer responses to draft
symbols that could represent the
nutrient content claim ‘‘healthy.’’ The
goal of the symbol is to help consumers
make more informed dietary choices.
(Comment 26) Several comments
recommended we change certain
aspects of the questions we include in
the experimental study. Some
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
comments suggested that we select
specific outcome measures, such as
purchase intent, sales data, ability of the
symbols to attract consumer attention,
long-term behavior change, consumer
perceptions of the taste and cost of
products bearing the ‘‘healthy’’ symbol,
the healthfulness of the products
consumers purchased, the number of
‘‘healthier’’ products purchased in a
shopping setting, and any unintended
consequences of the symbol.
One comment recommended adding
covariates, such as health status,
particularly for conditions that are
related to nutrition, such as diabetes,
weight status, and hypertension, to help
us understand responses. Regarding the
interpretation of measurements, one
comment suggested we avoid
‘‘believability’’ or ‘‘trustworthiness’’ as
indicators of which symbol can help
people make more informed dietary
choices, claiming that these are not
strong predictors of behavior. The
comment cited a study on cigarette pack
warning messages that found that
measures on the effects of the warning
message resulted more in intended
behavior change than did measures on
attitude perceptions (Ref. 4).
Another comment recommended FDA
provide an option for open-ended
responses to gauge consumers’
perceptions of ‘‘healthy.’’
(Response 26) The intended studies
cover the key measurements and
covariates that will help us understand
consumer perceptions of the symbols.
The comments did not provide, and we
are not aware of, evidence that adding
covariates or measurements would
enhance the quality, utility, or clarity of
the information we intend to collect. We
will evaluate our draft symbols based on
our analysis of all—not just a subset—
of these measurements. We
acknowledge that there are
measurements we are not including in
this research effort (e.g., long-term
behavior changes). These studies are
designed to explore consumer responses
to the draft symbols, and inclusion of
variables such as long-term behavior
changes would be premature.
We plan to use a variety of measures
to help understand the potential impact
of a voluntary FOP symbol for
‘‘healthy,’’ and intend to use
‘‘believability’’ and ‘‘trustworthiness’’ as
outcome measures because wellestablished scientific literature has
shown that consumers’ attitudes and
perceptions affect their behavior (Refs. 5
to 7). Additionally, we note that the
cigarette-pack study one comment cited
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
qualified its findings as unsure if the
same would be found in other message
or product scenarios (Ref. 4). Because
the published literature does not
indicate that ‘‘effects perception
measures’’ have been tested in the food
label domain, we will add some
questions to the experimental study to
evaluate their use as outcome measures
compared to ‘‘message effects
measures.’’
We disagree with the suggestion to
query consumers on their perception of
‘‘healthy.’’ Our research is designed to
test consumer responses to the draft
symbols, not determine consumer
perceptions of ‘‘healthy.’’
D. Comment Regarding Ways To
Minimize the Burden of the Collection
of Information on Respondents,
Including Through the Use of
Automated Collection Techniques,
When Appropriate, and Other Forms of
Information Technology, and FDA
Response
One comment discussed minimizing
the information collection burden on
respondents to our proposed ‘‘healthy’’
symbol research.
(Comment 27) One comment
supported the proposed research and
noted that the use of online surveys will
help alleviate participant and
administrative burden while ensuring
that the research reaches sufficient
participants.
(Response 27) We agree with the
comment for the purposes of this
research.
E. Nonresponsive Comments to the PRA
Some comments addressed aspects of
‘‘healthy’’ symbols that are outside the
scope of this information collection or
addressed issues other than the
‘‘healthy’’ symbol research. These
discussed, for example, the definition of
‘‘healthy,’’ potential impacts of the
‘‘healthy’’ nutrient content claim
generally, whether the symbols should
be voluntary or mandatory, and whether
we should develop an accompanying
consumer education campaign. These
are outside the scope of this information
collection, and we will not address
them here. Interested parties will have
an opportunity to comment on any
‘‘healthy’’ symbol we propose and any
proposed updated definition of the
nutrient content claim ‘‘healthy’’ in
response to their respective Federal
Register notices.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\28MRN1.SGM
28MRN1
Federal Register / Vol. 87, No. 59 / Monday, March 28, 2022 / Notices
17307
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Study
Study
Study
Study
Study
Study
Study
Study
1
2
1
2
1
2
1
2
Number of
responses per
respondent
Total annual
responses
Average burden per
response
Total hours
(Survey) Cognitive interview screener ...........
(Experiment) Cognitive interview screener 2 ..
(Survey) Cognitive interview ..........................
(Experiment) Cognitive interview ...................
(Survey) Pretest .............................................
(Experiment) Pretest ......................................
(Survey) ..........................................................
(Experiment) ...................................................
75
75
5
9
60
180
2,000
5,000
1
1
1
1
1
1
1
1
75
75
5
9
60
180
2,000
5,000
0.083 (5 minutes) ..
0.083 (5 minutes) ..
1 .............................
1 .............................
0.17 (10 minutes) ...
0.25 (15 minutes) ...
0.17 (10 minutes) ..
0.25 (15 minutes) ..
6
6
5
9
10
45
340
1,250
Total ......................................................................
........................
........................
........................
................................
1,671
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
2 Since Study 3 is identical to Study 2, only one set of cognitive interviews and pre-tests are needed.
II. References
jspears on DSK121TN23PROD with NOTICES1
The following references are on
display with the Dockets Management
Staff (see ADDRESSES) and are available
for viewing by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday; these are not available
electronically at https://
www.regulations.gov as these references
are copyright protected. Some may be
available at the website address, if
listed. FDA has verified the website
addresses, as of the date this document
publishes in the Federal Register, but
websites are subject to change over time.
1. Odsakoff, P.M., S.B. MacKenzie, N.P.
Podsakoff, 2012. ‘‘Sources of Method
Biases in Social Science Research and
Recommendations on How to Control
It.’’ Annual Review of Psychology, 63,
pp. 539–569.
2. Sheff, J.N., 2011. ‘‘Biasing Brands.’’
Cardozo Law Review, 32(4), pp. 1245–
1314.
3. Cohen, J., 1992. ‘‘A Power Primer.’’
Psychology Bulletin, 112(1), pp. 155–159.
4. Baig, S.A., S.M. Noar, N.C. Gottfredson, et
al., 2021. ‘‘Incremental Criterion Validity
of Message Perceptions and Effects
Perceptions in the Context of Antismoking Messages.’’ Journal of
Behavioral Medicine, 44, pp. 74–83.
5. Azjen, I., 2011. ‘‘The Theory of Planned
Behaviour: Reactions and Reflections.’’
Psychology and Health, 26(9), pp. 1113–
1127.
6. Azjen, I., 2014. ‘‘The Theory of Planned
Behaviour is Alive and Well, and Not
Ready to Retire: A Commentary on
Sniehotta, Presseau, and Araujo-Soares.’’
Healthy Psychology Review, 9(2), pp.
131–137.
7. Ajzen, I., 2016. ‘‘Consumer Attitudes and
Behavior: The Theory of Planned
Behavior Applied to Food Consumption
Decisions.’’ Italian Review of
Agricultural Economics, 70(2), pp. 121–
138.
VerDate Sep<11>2014
17:30 Mar 25, 2022
Jkt 256001
Dated: March 21, 2022.
Andi Lipstein Fristedt,
Deputy Commissioner for Policy, Legislation,
and International Affairs, U.S. Food and Drug
Administration.
[FR Doc. 2022–06419 Filed 3–25–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Solicitation of Nominations for
Organizational Representatives to the
Advisory Committee on Heritable
Disorders in Newborns and Children
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Request for nominations.
AGENCY:
HRSA is seeking nominations
from organizations to send
representatives to be a liaison to the
Advisory Committee on Heritable
Disorders in Newborns and Children
(ACHDNC or Committee). Selections
will be based on a review of the
organization’s subject area of expertise,
mission, relevancy, and benefit
provided relative to the Committee’s
purpose. The organizational
representatives are non-voting liaisons.
The Committee provides advice,
recommendations, and technical
information about aspects of heritable
disorders and newborn and childhood
screening to the Secretary of HHS.
DATES: Written nominations for
organizational representatives to the
ACHDNC must be received on or before
May 2, 2022.
ADDRESSES: Nomination packages must
be submitted electronically as email
attachments to Soohyun Kim, MPH,
CPH, Acting Designated Federal Officer
(DFO) at ACHDNC@hrsa.gov.
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Acting DFO Soohyun Kim, MPH, CPH;
Maternal and Child Health Bureau,
HRSA, 5600 Fishers Lane, Room 18–N–
38A, Rockville, MD 20857; 301–594–
4202; or ACHDNC@hrsa.gov. A copy of
the Committee charter and list of
current membership is available on the
Committee’s website: https://
www.hrsa.gov/advisory-committees/
heritable-disorders/.
ACHDNC
was established in 2003 to provide
advice and recommendations to the
Secretary on the development of
newborn screening activities,
technologies, policies, guidelines, and
programs for effectively reducing
morbidity and mortality in newborns
and children having, or at risk for,
heritable disorders. ACHDNC reviews
and reports regularly on newborn and
childhood screening practices for
heritable disorders, recommends
improvements in the national newborn
and childhood heritable screening
programs, recommends conditions for
inclusion in the Recommended Uniform
Screening Panel (RUSP), and fulfills
requirements stated in the authorizing
legislation. ACHDNC’s
recommendations regarding inclusion of
additional conditions/inherited
disorders for screening that, when
adopted by the Secretary, are included
in the RUSP, and constitute part of the
evidence-informed comprehensive
preventive health services guidelines
supported by HRSA pursuant to section
2713 of the Public Health Service Act
(42 U.S.C. 300gg–13). Under this
provision, non-grandfathered group
health plans and group and individual
health insurance issuers are required to
provide coverage without cost-sharing (a
co-payment, co-insurance, or
deductible) for preventive services for
plan years (i.e., in the individual
market, policy years) beginning on or
SUPPLEMENTARY INFORMATION:
E:\FR\FM\28MRN1.SGM
28MRN1
Agencies
[Federal Register Volume 87, Number 59 (Monday, March 28, 2022)]
[Notices]
[Pages 17300-17307]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-06419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0336]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Quantitative Research
on a Voluntary Symbol Depicting the Nutrient Content Claim ``Healthy''
on Packaged Foods
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing
that a proposed collection of information has been submitted to the
Office of Management and Budget (OMB) for review and clearance under
the Paperwork Reduction Act of 1995 (PRA).
DATES: Submit written comments (including recommendations) on the
collection of information by April 27, 2022.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under Review--Open for Public
Comments'' or by using the search function. The title of this
information collection is ``Quantitative Research on a Voluntary Symbol
Depicting the Nutrient Content Claim `Healthy' on Packaged Foods.''
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations,
Food and Drug Administration, Three White
[[Page 17301]]
Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852,
301-796-7726, [email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Quantitative Research on a Voluntary Symbol Depicting the Nutrient
Content Claim ``Healthy'' on Packaged Foods
OMB Control Number 0910-NEW
I. Background
Section 403(r)(1)(A) of the Federal Food, Drug, and Cosmetic Act
(FD&C Act) (21 U.S.C. 343(r)(1)(A)) permits the use of label and
labeling claims that characterize the level of a nutrient in a food
when the claims are made in accordance with FDA's regulations. Such
claims are referred to as ``nutrient content claims.'' We have issued
regulations under section 403(r)(1)(A) of the FD&C Act describing
``implied nutrient content claims'' as those that, among other things,
suggest that a food, because of its nutrient content, may help
consumers maintain healthy dietary practices (21 CFR 101.65(d)(1)(i).
The rule finalizing these claims also describes implied claims, in
part, as those that imply that a food, because of its nutrient content,
may be useful in achieving a total diet that conforms to current
dietary recommendations (``Food Labeling: Nutrient Content Claims,
General Principles, Petitions, Definition of Terms,'' 58 FR 2302 at
2374, January 6, 1993)). We have determined that a claim that a food,
because of its nutrient content, may be useful in maintaining healthy
dietary practices is clearly a claim that characterizes the level of
nutrients in that food. The claim is essentially saying that the level
of nutrients in the food is such that the food will contribute to good
health (58 FR 2302 at 2375). In 1994, we issued a definition of
``healthy'' as an implied nutrient content claim (59 FR 24232, May 10,
1994); the regulation is codified at 21 CFR 101.65(d)(2).
FDA seeks to improve dietary patterns in the United States to help
reduce the burden of diet-related chronic diseases and advance health
equity. We are committed to accomplishing this by, in part, empowering
consumers with information to make more informed dietary choices. To
help advance these goals, we are exploring the development of a graphic
symbol to help companies communicate and consumers identify packaged
food products that meet FDA's definition of ``healthy.'' The symbol
would be a graphic representation of the nutrient content claim
``healthy'' and, like the implied nutrient content claim ``healthy''
itself, would be voluntary for packaged food companies. Companies could
voluntarily use the symbol on food products that meet FDA's definition
of ``healthy.''
In 2019 and 2020, FDA conducted a review of the literature on
front-of-package (FOP) nutrition-related symbols and conducted a series
of focus groups to test symbol concepts and draft FOP symbols (see
Docket No. FDA-2021-N-0336 for the literature review and a table of
draft FOP symbols).
As part of our efforts to promote public health, we intend to
conduct two consecutive quantitative research studies--a survey (Study
1) and an experimental study (Study 2) to explore consumer responses to
the draft FOP symbols that companies could voluntarily use on a food
product as a graphic representation of the nutrient content claim
``healthy.'' If research results suggest the need, the symbols will be
fine-tuned following the survey and again following the experimental
study. Study 1 will use non-probability survey methods, using a web-
based panel to draw a sample of 2,000 U.S. adults ages 18 and older who
self-identify as primary food shoppers. The sample will be balanced to
the demographics of the U.S. population. The survey instrument will
focus on clarity, relevance, and appeal of a set of symbols.
Study 2 will be a controlled, randomized experiment that will use a
15-minute web-based questionnaire to collect information from 5,000
U.S. adult members of an online consumer panel. Conditions for Study 2
will be: (1) A set of draft FOP symbols, including ``no-symbol''
controls; (2) three types of mock food products (i.e., a breakfast
cereal, a frozen meal, and a canned soup); (3) a ``no-information''
condition where no explanation of the symbol is provided; and; (4) a
Uniform Resource Locator (URL) condition, in which a URL is tested
alongside the symbol. Each participant in Study 2 will be randomly
assigned to a condition, which will include viewing a label image and
responding to various measures of the symbol's effectiveness. Measures
of response in the experiment will include product perceptions (e.g.,
healthfulness and contribution to a healthy diet), label perceptions
(e.g., believability, trustworthiness, message effects), and purchase/
choice questions. The instrument will also collect information from
participants about their history of purchasing or consuming similar
products; nutrition knowledge; dietary interests; motivation regarding
label use; health status; and demographic characteristics.
The studies are part of our continuing effort to enable consumers
to make informed dietary choices and construct healthful diets. We
intend to use the results to inform our continued exploration of a
symbol manufacturers could voluntarily use to represent the nutrient
content claim ``healthy'' on the food label. We will not use the
results to develop population estimates.
Description of Respondents: Respondents to this collection of
information include members of the general public.
In the Federal Register of May 7, 2021 (86 FR 24629), FDA published
a 60-day notice requesting public comment on the proposed collection of
information (``60-day notice''). We received 43 comments, 27 of which
were PRA-related. The remaining comments were non-responsive to the
four PRA topics, and so we will not address them in this document.
A. Comments Regarding the Necessity and Practical Utility of the
Information Being Collected and FDA Response
Several comments addressed the necessity and practical utility of
collecting information on a voluntary symbol depicting the nutrient
content claim ``healthy'' on packaged foods.
(Comment 1) Some comments supported FDA's proposed collection of
information through the three proposed quantitative consumer research
studies. Some comments expressly supported FDA's end research goal of
enabling consumers to make informed dietary choices and construct
healthful diets. Some supported FDA's intention to understand consumer
responses to draft FOP symbols and gather data and other information to
inform our thinking on a ``healthy'' symbol. Many comments indicated
the importance of conducting this research before taking regulatory
action on any symbol. Some comments supported conducting the research
in conjunction with development of a proposed rule that would update
the definition of ``healthy'' on food packages.
Other comments opposed FDA research on a ``healthy'' symbol. Some
of these comments suggested the research is unnecessary, claiming that
a single food is not ``healthy'' or ``unhealthy,'' that overall diet
matters more than individual foods, or that symbols are industry
marketing. A few comments suggested a ``healthy'' symbol could be
particularly misleading to, or misinterpreted by, people who are
[[Page 17302]]
experiencing eating disorders. Some comments also questioned whether a
``healthy'' symbol would: (1) Have a positive and meaningful impact on
improving health or (2) lead consumers to overconsume foods bearing the
symbol.
(Response 1) We intend to conduct this research now, in conjunction
with further work on updating our definition of the claim ``healthy''
and before taking regulatory action on any symbol. Our intended
research will help us better understand how consumers might respond to
and use a graphic symbol to identify packaged food products that meet
our definition of ``healthy.'' This research will help address many
points raised in the comments, such as how consumers might react to and
understand a ``healthy'' symbol and misinterpretations they may have.
While we agree that there are some symbols that may be used
exclusively for industry marketing, companies could use any FDA
``healthy'' symbol we develop and finalize only when the product
displaying the symbol meets FDA's regulatory definition of ``healthy.''
This could help consumers make more informed dietary choices and
construct healthful diets. The comments claiming that a single food is
not ``healthy'' or ``unhealthy'' and that overall diet matters more
than individual foods are commenting on the ``healthy'' claim itself,
which we do not intend to test in this research. Rather, we intend to
test consumer reactions to symbols that could be a graphic
representation of the claim. Nonetheless, we note that a ``healthy''
symbol, such as the ones FDA is exploring in our research, could help
consumers choose food products, as part of their overall diet, that
meet FDA's regulatory definition of ``healthy.'' The research is not
designed to study long-term health effects or consumer consumption
patterns. We reiterate that this research is about graphical
representations of the nutrient content claim ``healthy''--in other
words, we intend to study only the symbol, not the claim itself.
Depending on the results of this data collection, we may decide to test
additional symbols or revise our current symbols.
(Comment 2) Many comments expressed a preference for conducting the
research after we revise our regulatory definition of ``healthy,'' as
they wondered whether the definition of the claim could influence both
the design and consumer understanding of the symbol. Some expressed
concern that testing a symbol without clearly communicating what the
symbol means could lead to ambiguous results. One comment expressed
concern that, by conducting testing only on the symbols in the notice,
we would not consider testing any other symbols in the future. A few
comments contended that FDA's testing would be invalid if the mock
products used in testing do not meet FDA's updated ``healthy''
definition.
(Response 2) FDA has an existing definition for the claim
``healthy,'' and in the Federal Register of September 28, 2016, we
announced our intent to exercise enforcement discretion around some
criteria for the claim (see ``Use of the Term `Healthy' in the Labeling
of Human Food Products: Guidance for Industry,'' 81 FR 66527). However,
as part of this data collection, we have included experimental
conditions in which participants will read general information
outlining the use of the claim ``healthy'' only for purposes of this
study. This will help us better understand how consumers might respond
to the symbols we are proposing to test if participants understand a
``healthy'' definition, even if not necessarily an updated definition.
While the symbol is intended to represent the nutrient content claim
``healthy,'' our research on the symbol is not dependent on specific
criteria for ``healthy.'' We are researching general consumer
perceptions and impressions of the symbols themselves, not the
definition that may underly those symbols, and as such, we do not need
to wait until we have a final, updated regulatory definition of
``healthy'' before conducting this research. Moreover, the symbols
being tested would not need to be modified with a changing definition
of ``healthy;'' the symbol would remain a simple graphic representation
of the ``healthy'' claim.
Regarding the claim that our testing would be invalid if the mock
products used in testing do not meet FDA's updated ``healthy''
definition, our mock products represent broad and basic food
categories. They include foods such as vegetables and whole grains with
limited nutrients of concern (e.g., sodium or saturated fat) that would
meet our current definition of ``healthy'' and would help consumers
build a diet consistent with the Dietary Guidelines for Americans,
2020-2025.
B. Comments Regarding the Accuracy of Our Burden Estimates, Including
the Validity of the Methodology and Assumptions Used, and FDA Response
Many comments discussed the accuracy of FDA's estimate of the
burden for this information collection, including the validity of FDA's
methodology and the assumptions used.
(Comment 3) Several comments alleged that we provided limited
details about our proposed research studies and encouraged us to
publish additional information on the proposed scope and methodology of
our consumer research to allow for more comprehensive input from
experts in the field of consumer research. One comment suggested we
``pre-register'' details of the proposed studies on AsPredicted.org or
ClinicalTrials.gov so that stakeholders could better understand the
primary outcome of the research, hypotheses, analytic plan, and power
analysis used.
(Response 3) We described the research in the 60-day notice,
providing information on research design, measures, sampling, and
sample size. Many comments substantively addressed these issues, and so
we believe there was enough information about the studies in the 60-day
notice for the public--including consumer researchers--to comment on
the research.
We specified in the 60-day notice that we intend to use the results
to inform our continued exploration of a symbol manufacturers could
voluntarily use to represent the nutrient content claim ``healthy'' on
the food label (86 FR 24629 at 24631). The comment did not provide
sufficient information regarding additional details that it believed
necessary for stakeholders to better understand this primary outcome,
hypotheses, analytic plan, and power analysis used, and it did not
explain what additional details might be available via pre-registration
that would not be available in our Federal Register notices. Therefore,
we are unable to provide those details here, and we also decline to
pre-register our studies.
(Comment 4) One comment questioned the ordering of the quantitative
research, asking why the experimental studies come before the surveys.
Other comments suggested we use the two surveys to test draft symbols
first to narrow down options and test the ``final'' symbols in the
experiment, or to conduct preliminary research to narrow the options
for the experiment.
(Response 4) We conducted several phases of qualitative research to
solicit input from consumers, allowing us to evaluate symbol prototypes
and design elements to learn what resonated with consumers. Through
that process we narrowed our draft symbol options. After considering
public comments, we have reconsidered the order of the research, and
plan to conduct one survey with a larger sample size (instead of two
surveys with smaller sample sizes each) before the experimental study.
In other words, we will reorder
[[Page 17303]]
the studies and combine the two surveys into one, which will allow us
to test all symbols in a single survey. While our proposed information
collection is intended to help us better understand how consumers might
respond to and use a graphic symbol that indicates packaged food
products meet FDA's definition of ``healthy,'' and all the draft
symbols we proposed to test would allow us to do that, we expect
conducting a single survey first will help us further revise and narrow
down the set of symbols.
(Comment 5) One comment suggested we use a more naturalistic study
environment, such as an online store setting, instead of using images.
(Response 5) Online store settings and other naturalistic study
environments have been successfully employed in some studies on food
labeling effects. One advantage of employing such naturalistic study
environments is that they more closely reflect participants' actual
shopping experience. However, there are substantial additional costs
associated with using such research settings, and results in these
settings generally do not differ appreciably from results garnered
through the simple random-assignment-to-condition design that we
proposed. Therefore, we decline to change our study environment.
(Comment 6) One comment suggested that FDA separate different
aspects of the symbols to isolate consumer perceptions of the word
``healthy,'' the graphic itself, and the graphic accompanied by the
word ``FDA.'' One comment suggested that FDA should test each symbol
with and without ``FDA.''
(Response 6) Separating each aspect of the symbols for our testing
would increase the number of conditions exponentially, making the
design impractical. We instead elected to use a full factorial design
with simple random assignment to condition, to give us results on the
performance of the various symbol designs. Using random assignment to
condition, we may be able to eliminate some symbols without needing to
test particular attributes in any one symbol. We may consider alternate
study designs when we have a narrower set of symbols.
One finding of our literature review was that institutional
endorsement may be related to greater confidence in the symbol. Our
focus group research affirmed that participants regarded symbols with
``FDA'' as more trustworthy than symbols without ``FDA.'' Therefore,
for the intended research, we are testing draft symbols with ``FDA.''
We may consider additional research on this point depending on the
results.
(Comment 7) One comment recommended using images of real food
products in the experimental studies instead of using mock product
images.
(Response 7) FDA does not agree with the recommendation to use
images of real products in the experimental studies. Mock images remove
the potential for brand biases, a source of response error that has
been demonstrated to affect the way individuals answer survey
questions. Mock food product labels psychologically remove the salience
of branded product informational cues present in the retrieval stage of
the response process (Refs. 1 and 2). Additionally, the mock product
labels we designed are visually similar to labels consumers could
expect to see in stores for each given product category. We confirmed
this assertion in our qualitative testing by noting that participants
perceived the mock product labels as ones with which they were
unfamiliar, but which were plausible for the food product depicted.
(Comment 8) One comment suggested that we should assess ``multi-
tier symbols'' in addition to the symbols we intend to test. The
comment suggested that multi-tier symbols are those that use, for
example, an increasing number of stars to indicate to the consumer that
a choice is ``good,'' ``better,'' or ``best.'' The comment argued that
a multi-tiered approach could encourage consumers to make incremental
improvements in their diets, enable manufacturers to reformulate
products to meet the initial tier of the system, and increase the
number of foods with at least some healthful benefits that could carry
a symbol.
Another comment suggested that FDA consider a symbol that warns
consumers about high levels of unhealthy nutrients. Another comment
asserted that we should also test what it suggested were more neutral
FOP labels, such as traffic lights, nutrition scoring symbols, and
warning symbols, to better assist consumers in making healthy choices
and motivate manufacturers to make healthier foods.
(Response 8) For the purpose of this study, we are testing only
symbols that would be a graphic representation of the nutrient content
claim ``healthy''--a food that could bear that claim could also bear
the symbol. FDA's systematic literature review suggested that a summary
indicator--the type we are proposing to test--would have the greatest
utility to depict the ``healthy'' claim to a broad array of consumers,
especially those with lower education or lower health literacy. As
such, we disagree that we should test other kinds of symbols to depict
the nutrient content claim ``healthy.'' We are testing different draft
symbol designs based on our literature review and the feedback we
collected through our focus group research. Our current study plans are
limited to testing summary symbols depicting the nutrient content claim
``healthy'' to get reactions to design elements and to reduce the
current number of symbols under consideration. Because there are no
``healthy'' tiers in the nutrient content claim, we decline to test a
tiered symbol.
(Comment 9) One comment encouraged us to consider testing the
``healthy'' symbol alongside other current voluntary FOP labels--rather
than as the only symbol on a package--to determine the effect of other
FOP labels on the efficacy of the ``healthy'' symbol.
(Response 9) Our studies are designed to test general consumer
responses to the symbols presented. Testing additional variables, such
as the effect of other packaging elements on the symbols, is outside
the scope of this research. We may decide to test ``healthy'' symbols
alongside other FOP symbols in later research depending on the results
from this data collection.
(Comment 10) One comment recommended randomizing participants to
see subgroups of symbols, claiming it would be an efficient use of
resources.
(Response 10) FDA agrees with the recommendation that participants
be randomly assigned; however, we disagree with the recommendation to
have participants view subgroups of symbols. We plan to randomly assign
participants to see a single symbol condition, including product type,
information on the definition of healthy, URL/no-URL, and set of
symbols. Viewing a single symbol condition precludes the effects of
biases that may result from having viewed and responded to questions
about one symbol affecting responses about another symbol (Ref. 1).
Therefore, even if we might use fewer resources by assigning
participants to see subgroups of symbols, the practice would introduce
biases and confounds that could make interpreting the results very
difficult.
(Comment 11) One comment recommended incorporating time limits for
a choice task to better mimic real-life scenarios where consumers have
only limited time to shop.
(Response 11) The current experimental study design is random
assignment to condition with no ``choice task.'' While time-constraint
[[Page 17304]]
studies can be useful to test certain variables, our research goal is
for the participants to provide thoughtful responses, unaffected by the
stress that a time limit could impose.
(Comment 12) A few comments recommended that the studies be
adequately powered to enable FDA to do appropriate statistical
analysis.
(Response 12) Our studies are designed to have the appropriate
statistical power to conduct all necessary statistical analysis. We
will test hypotheses related to between-label differences. We will
impose no a priori direction of differences, if any (i.e., we assume
all tests are two-tailed). The target sample size (5,000 for the
experimental study and 2,000 for the survey) will yield enough
observations to provide adequate power to identify 4-way interactions
of a medium size (Ref. 3).
(Comment 13) One comment recommended that we test the draft
``healthy'' symbols in the context of restaurants.
(Response 13) Our research plans include testing symbols solely on
packaged foods. Testing ``healthy'' on a packaged food label versus in
a restaurant minimizes the many confounding factors inherent in
studying claims in a restaurant environment, such as the enormous
variance in size and content of materials used to sell restaurant food.
Keeping the studies limited to packaged food labels allows FDA to
better isolate various effects of the symbols to strictly test consumer
perceptions about the symbols. Additionally, as we noted in response to
another comment, we have no reason to believe that adding additional
test product categories would change the study outcomes given our goal
of testing consumer responses to the symbols.
(Comment 14) Some comments recommended that FDA include more than
three mock product types in the experimental studies because of the
potential that consumer perceptions of a ``healthy'' symbol might be
different on different products. One comment suggested including a
variety of food categories in the studies, while a few other comments
recommended including specific product categories, including beverages
and fresh produce, so FDA could assess consumer reactions to, or
preferences for placement of, a symbol on those products.
(Response 14) FDA disagrees with the recommendation to add more
product types to the studies. We are proposing to test ``healthy''
symbols on a set of mock products that belong to large food categories,
with many product types within each category. The broad product
categories for those mock products are likely to contain multiple
products that currently meet FDA's regulatory definition of
``healthy.''
For our research, we chose three packaged foods that are commonly
consumed and that are clearly distinct food types. The selected
products will give us sufficient information on general consumer
responses to the symbols to continue development of a proposed
``healthy'' symbol. We also note that adding any products would
increase the scope and cost of the studies while providing limited new
information and that the comments provided no evidence that additional
test products from other food categories would impact our study
outcome.
We decline to include a beverage as one of the mock products. While
beverages that meet FDA's definition of ``healthy'' could bear any
``healthy'' symbol we finalize, the same is true of any packaged food,
and as we explained above, we have no reason to believe that adding
additional test product categories would change the study outcomes. We
decline to add fresh produce to the studies for the same reasons.
(Comment 15) A few comments recommend comparing foods with a
``healthy'' symbol and foods that may have healthful attributes but do
not meet the regulatory definition of ``healthy,'' to evaluate whether
use of the symbol might result in discouraging purchase of foods that
have important nutrients but that do not meet the definition of
``healthy.'' Another comment suggested testing a variety of products
(``healthier'' and ``less healthy'') for each food product category
included in the studies.
(Response 15) The studies are not designed to test purchasing
behavior, and so we decline to add mock products for that purpose.
Rather, this research is designed to test general consumer responses to
the symbols themselves. Additionally, a product could only bear the
symbol if it qualified to bear the ``healthy'' claim itself--the symbol
is a graphic representation of the claim--and we are not testing the
claim definition or its effects here.
One of the study assumptions is that, like the nutrient content
claim ``healthy,'' any food bearing a ``healthy'' symbol on its label
must meet the regulatory definition of ``healthy.'' Therefore, to test
consumer responses to the symbols, we do not need to test the ancillary
effects of a ``healthy'' symbol on foods that do not bear the claim.
Moreover, FDA intends to test ``healthy'' symbols on a set of mock
products whose product categories are likely to contain multiple
products that currently meet FDA's regulatory definition of
``healthy''--we are making no claims about the relative healthfulness
of any product. Using these mock products in our research will provide
us with sufficient information to understand how consumers might
respond to a ``healthy'' symbol on food packaging, and that information
is our goal with these studies. Testing the selected products will give
us sufficient information to continue development of a proposed
``healthy'' symbol.
The comment did not provide an explanation for its recommendation
to test ``healthier'' and ``less healthy'' products for each food
product category. We are not testing ``healthier'' and ``less healthy''
versions of a given product in this research effort, as the goal of the
research is to gauge participants' reactions to a symbol. Additionally,
we are working on updating our definition of ``healthy'' and will
describe our proposed updated definition in any related rulemaking. It
would be inappropriate to assign relative ``healthfulness'' to
comparator products. Products bearing the ``healthy'' symbol, which
would be a graphic version of the nutrient content claim ``healthy,''
would have to meet the criteria for using the claim.
(Comment 16) One comment noted a symbol with the term ``FDA'' may
cause confusion if that symbol is used on any products regulated by the
U.S. Department of Agriculture (USDA) and urged us to consider the
potential for such confusion in our research. Another suggested that we
engage with the Food Safety and Inspection Service during our proposed
consumer research on the ``healthy'' symbol to develop a symbol that
could apply to all products that meet the ``healthy'' claim criteria.
(Response 16) We cannot comment on whether or how USDA might allow
an FDA ``healthy'' symbol on the products it regulates that meet FDA's
definition of ``healthy.'' However, we intend to coordinate with our
federal partners, including USDA, as appropriate, as we continue our
work on a ``healthy'' symbol.
(Comment 17) A few comments asserted it was important to consider
the symbols' placement on packaging and noted that food packaging size,
type, and appearance vary, suggesting that FDA should study how
consumers may respond to a ``healthy'' symbol on a wider variety of
packaging formats than are currently proposed for the studies. One
comment suggested testing the symbol on different locations on the
package and with varying prominence.
[[Page 17305]]
Another encouraged flexibility in specified requirements (e.g.,
placement, type size, color format, scannable images) surrounding the
FOP symbol.
(Response 17) We anticipate that any ``healthy'' symbol we propose
would be standardized in certain ways. However, the purpose of this
research is to gauge consumer responses to the symbols we are testing,
not to decide on a single symbol, its potential placement on packaging,
or what aspects we would require, should a company choose to use the
symbol.
(Comment 18) A few comments suggested we include questions or
conduct additional research to assess the potential for consumer
misunderstanding of the symbols. Some comments suggested that we
investigate whether consumer perceptions of some symbols might imply
messages other than ``healthy'' (such as ``organic,'' ``natural,''
``plant-based,'' and ``minimally processed'') or whether the symbols we
are testing may appear similar to other existing or abandoned symbols
(such as the USDA Organic Seal, Smart Choices, or any of USDA's
bioengineered food symbols). One comment claimed that a lack of
legibility of the text in the symbol could cause consumer confusion.
Another comment recommended that FDA avoid leaf or nature imagery in
the symbol because it could imply that the product is plant-based,
``natural,'' or unprocessed. One comment encouraged us to examine how
appealing the symbols are to consumers, and another comment described
the proposed symbols as too simplistic.
(Response 18) We have selected study designs and draft symbols that
we expect, when used together, will reveal how consumers will react
when they see such symbols on a food label. We included questions in
our studies on what the symbols lead participants to believe about the
products bearing them. We also expect to hear from participants whether
the symbols we are testing are perceived as too complex, too
simplistic, or invoke concepts other than ``healthy.''
We agree that any symbol we propose should be legible and minimize
imagery that our research indicates could widely lead consumers to
think the symbol means something unintended. As such, we will add an
open-ended question to the experimental study asking what the symbol
brings to mind to help determine if any symbols should be removed from
consideration or revised on this basis. Moreover, we agree that the FDA
symbol design for ``healthy'' should not be easily confused with other
existing symbols and should be viewed as professional and credible by
consumers. We expect to get some data on these points through this
round of testing and may undertake further research before we make any
formal regulatory decision on a symbol.
(Comment 19) One comment suggested that FDA test other terms
besides ``healthy,'' such as ``nourishing'' or ``nutrient-dense.''
(Response 19) We are not testing the nutrient content claim
``healthy;'' rather, we are testing consumer responses to graphic
representations of the claim. We similarly do not intend to test other
terms.
(Comment 20) Several comments supported conducting research on the
use of an accompanying URL with the ``healthy'' symbol; however, others
stated the purpose for including a URL was unclear, and one comment
expressed concern that a URL would not work as well in a brick-and-
mortar retail setting. Another comment stated that future labeling
could include the use of other technologies, such as a quick response
(QR) code or digital watermark, to provide consumers access to all the
labeling information included on the package and suggested that we
incorporate digital disclosure flexibility into our labeling
regulations because technology continues to evolve. Other comments
suggested that consumers may not have internet access in stores or may
not know how to use QR codes, while another comment suggested that
researchers could develop unique QR codes for each condition and track
participant use.
(Response 20) Our research efforts on the ``healthy'' symbol are
intended to collect sufficient data for the development and
finalization of a ``healthy'' symbol. We are studying several
dimensions of a proposed symbol, including the inclusion of a URL as
part of the symbol. This research will help us better understand study
participants' reactions to and understanding of those different
elements.
Our preliminary research indicated that participants are interested
in learning more about the symbols, and a URL can serve as a
representation to participants that more information is available. The
current study design proposes to test a URL alongside some of the
symbols to gauge the ability of the URL to indicate that information
about the symbol is available and to assess the degree to which a URL
improves confidence and trust in the symbol. We are not studying
participants' actual ability to access the URL in stores or elsewhere.
We are also not considering inclusion of other technologies, such as a
QR code or digital watermark, in this information collection because a
URL will help us gauge whether participants want a way to access
additional information about the symbol. Further, a QR code or digital
watermark would not indicate government involvement in the way a URL
ending ``.gov'' may, and we are interested in how participants will
respond to a ``.gov'' URL.
While we agree that technology changes over time, we are only
studying consumer responses to the symbols in this research. It would
be premature to comment on any requirements surrounding any symbol we
might propose. However, we could consider other digital elements, such
as QR codes or digital watermarks, in future research depending on our
future research goals.
(Comment 21) Some comments raised concerns that the use of FDA's
name as part of the ``healthy'' symbol. The comments said that the use
of FDA's name could create the appearance of an FDA endorsement of a
given food.
(Response 21) We are testing draft symbols with ``FDA.'' We note
that we are studying several dimensions of a proposed symbol to help us
better understand study participants' reactions to and understanding of
those different elements, including any impression of an FDA
endorsement.
(Comment 22) A few comments expressed uncertainty as to whether FDA
research participants would come from a nationally representative
sample and recommended paying particular attention to or using quota
samples similar to the demographic breakdown of the U.S. population
regarding sex, age, race/ethnicity, income, and education. Some
comments also stated that FDA should consider oversampling from certain
groups at highest risk for dietary-related disparities, asserting that
it is important to ensure that any proposed healthy symbol works well
among all populations. One comment noted this is especially important
for lower-education groups who, the comment asserted, may be less
likely to use or understand the package's nutrition label. Some
comments also requested that FDA screen participants to ensure a sample
large enough to collect responses from food-allergic individuals,
caregivers to food-allergic individuals, and parents.
(Response 22) We designed our studies to test consumer responses to
draft symbols in a randomized controlled setting, with participants
drawn from a general population. Our research collection is not
intended to produce population estimates. However, we intend to select
the samples in each study to be reflective of the general U.S.
[[Page 17306]]
population (e.g., sex, race/ethnicity). We believe our approach is
reasonable because any ``healthy'' symbol we finalize will be available
to the general U.S. population.
(Comment 23) One comment suggested that we test a Spanish language
version of the symbol and consider whether including ``FDA'' as part of
the symbol would resonate with consumers of products sold in other
countries.
(Response 23) Our regulations, at 21 CFR 101.15(c), generally
require that the labeling of all food offered for sale in the United
States be in English, and outline requirements for manufacturers that
also choose to label their products in additional languages. Because we
generally require only English labeling, and manufacturers may choose
whether to use or include foreign-language labeling, we are testing
only an English-language version of the symbol in this set of studies.
As for products sold in other countries, the nutrient content claim
``healthy,'' and any related symbol we finalize, are specifically for
products marketed and sold in the United States. We decline to comment
on marketing and sales in, or the food labeling requirements of, other
countries.
(Comment 24) One comment argued that we should not generalize the
results from this study to all FOP label systems.
(Response 24) We agree that findings from this research should not
be generalized to all FOP label systems.
C. Comments Regarding Ways To Enhance the Quality, Utility, and Clarity
of the Information To Be Collected, and FDA Response
Several comments suggested ways to enhance the quality, utility,
and clarity of the information about ``healthy'' symbols to be
collected.
(Comment 25) Some comments stated FDA should conduct thorough
research regarding the development and finalization of a symbol for
``healthy,'' and should collect comprehensive data so that FDA's final
decision promotes health.
(Response 25) FDA agrees with the comments. Our research goal is to
explore consumer responses to draft symbols that could represent the
nutrient content claim ``healthy.'' The goal of the symbol is to help
consumers make more informed dietary choices.
(Comment 26) Several comments recommended we change certain aspects
of the questions we include in the experimental study. Some comments
suggested that we select specific outcome measures, such as purchase
intent, sales data, ability of the symbols to attract consumer
attention, long-term behavior change, consumer perceptions of the taste
and cost of products bearing the ``healthy'' symbol, the healthfulness
of the products consumers purchased, the number of ``healthier''
products purchased in a shopping setting, and any unintended
consequences of the symbol.
One comment recommended adding covariates, such as health status,
particularly for conditions that are related to nutrition, such as
diabetes, weight status, and hypertension, to help us understand
responses. Regarding the interpretation of measurements, one comment
suggested we avoid ``believability'' or ``trustworthiness'' as
indicators of which symbol can help people make more informed dietary
choices, claiming that these are not strong predictors of behavior. The
comment cited a study on cigarette pack warning messages that found
that measures on the effects of the warning message resulted more in
intended behavior change than did measures on attitude perceptions
(Ref. 4).
Another comment recommended FDA provide an option for open-ended
responses to gauge consumers' perceptions of ``healthy.''
(Response 26) The intended studies cover the key measurements and
covariates that will help us understand consumer perceptions of the
symbols. The comments did not provide, and we are not aware of,
evidence that adding covariates or measurements would enhance the
quality, utility, or clarity of the information we intend to collect.
We will evaluate our draft symbols based on our analysis of all--not
just a subset--of these measurements. We acknowledge that there are
measurements we are not including in this research effort (e.g., long-
term behavior changes). These studies are designed to explore consumer
responses to the draft symbols, and inclusion of variables such as
long-term behavior changes would be premature.
We plan to use a variety of measures to help understand the
potential impact of a voluntary FOP symbol for ``healthy,'' and intend
to use ``believability'' and ``trustworthiness'' as outcome measures
because well-established scientific literature has shown that
consumers' attitudes and perceptions affect their behavior (Refs. 5 to
7). Additionally, we note that the cigarette-pack study one comment
cited qualified its findings as unsure if the same would be found in
other message or product scenarios (Ref. 4). Because the published
literature does not indicate that ``effects perception measures'' have
been tested in the food label domain, we will add some questions to the
experimental study to evaluate their use as outcome measures compared
to ``message effects measures.''
We disagree with the suggestion to query consumers on their
perception of ``healthy.'' Our research is designed to test consumer
responses to the draft symbols, not determine consumer perceptions of
``healthy.''
D. Comment Regarding Ways To Minimize the Burden of the Collection of
Information on Respondents, Including Through the Use of Automated
Collection Techniques, When Appropriate, and Other Forms of Information
Technology, and FDA Response
One comment discussed minimizing the information collection burden
on respondents to our proposed ``healthy'' symbol research.
(Comment 27) One comment supported the proposed research and noted
that the use of online surveys will help alleviate participant and
administrative burden while ensuring that the research reaches
sufficient participants.
(Response 27) We agree with the comment for the purposes of this
research.
E. Nonresponsive Comments to the PRA
Some comments addressed aspects of ``healthy'' symbols that are
outside the scope of this information collection or addressed issues
other than the ``healthy'' symbol research. These discussed, for
example, the definition of ``healthy,'' potential impacts of the
``healthy'' nutrient content claim generally, whether the symbols
should be voluntary or mandatory, and whether we should develop an
accompanying consumer education campaign. These are outside the scope
of this information collection, and we will not address them here.
Interested parties will have an opportunity to comment on any
``healthy'' symbol we propose and any proposed updated definition of
the nutrient content claim ``healthy'' in response to their respective
Federal Register notices.
FDA estimates the burden of this collection of information as
follows:
[[Page 17307]]
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden per response Total hours
respondents respondent responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Study 1 (Survey) Cognitive interview screener 75 1 75 0.083 (5 minutes)........................ 6
Study 2 (Experiment) Cognitive interview 75 1 75 0.083 (5 minutes)........................ 6
screener \2\.
Study 1 (Survey) Cognitive interview......... 5 1 5 1........................................ 5
Study 2 (Experiment) Cognitive interview..... 9 1 9 1........................................ 9
Study 1 (Survey) Pretest..................... 60 1 60 0.17 (10 minutes)........................ 10
Study 2 (Experiment) Pretest................. 180 1 180 0.25 (15 minutes)........................ 45
Study 1 (Survey)............................. 2,000 1 2,000 0.17 (10 minutes)........................ 340
Study 2 (Experiment)......................... 5,000 1 5,000 0.25 (15 minutes)........................ 1,250
----------------------------------------------------------------------------------------------------------
Total.................................... .............. .............. .............. ......................................... 1,671
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
\2\ Since Study 3 is identical to Study 2, only one set of cognitive interviews and pre-tests are needed.
II. References
The following references are on display with the Dockets Management
Staff (see ADDRESSES) and are available for viewing by interested
persons between 9 a.m. and 4 p.m., Monday through Friday; these are not
available electronically at https://www.regulations.gov as these
references are copyright protected. Some may be available at the
website address, if listed. FDA has verified the website addresses, as
of the date this document publishes in the Federal Register, but
websites are subject to change over time.
1. Odsakoff, P.M., S.B. MacKenzie, N.P. Podsakoff, 2012. ``Sources
of Method Biases in Social Science Research and Recommendations on
How to Control It.'' Annual Review of Psychology, 63, pp. 539-569.
2. Sheff, J.N., 2011. ``Biasing Brands.'' Cardozo Law Review, 32(4),
pp. 1245-1314.
3. Cohen, J., 1992. ``A Power Primer.'' Psychology Bulletin, 112(1),
pp. 155-159.
4. Baig, S.A., S.M. Noar, N.C. Gottfredson, et al., 2021.
``Incremental Criterion Validity of Message Perceptions and Effects
Perceptions in the Context of Anti-smoking Messages.'' Journal of
Behavioral Medicine, 44, pp. 74-83.
5. Azjen, I., 2011. ``The Theory of Planned Behaviour: Reactions and
Reflections.'' Psychology and Health, 26(9), pp. 1113-1127.
6. Azjen, I., 2014. ``The Theory of Planned Behaviour is Alive and
Well, and Not Ready to Retire: A Commentary on Sniehotta, Presseau,
and Araujo-Soares.'' Healthy Psychology Review, 9(2), pp. 131-137.
7. Ajzen, I., 2016. ``Consumer Attitudes and Behavior: The Theory of
Planned Behavior Applied to Food Consumption Decisions.'' Italian
Review of Agricultural Economics, 70(2), pp. 121-138.
Dated: March 21, 2022.
Andi Lipstein Fristedt,
Deputy Commissioner for Policy, Legislation, and International Affairs,
U.S. Food and Drug Administration.
[FR Doc. 2022-06419 Filed 3-25-22; 8:45 am]
BILLING CODE 4164-01-P